- Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients
-
You CW, Baek HJ, Park SK, Park YS, Shin HJ, Engl W, Tangada S
- KMID: 2459385
- Blood Res.
- 2019 Sep;54(3):198-203.
- doi: 10.5045/br.2019.54.3.198
BACKGROUND: The efficacy and safety of extended half-life, full-length, pegylated recombinant factor VIII rurioctocog alfa pegol [BAX 855, ADYNOVATE (USA)/ADYNOVI (Europe); Baxalta US Inc., a Takeda company, Lexington, MA, USA]... -
- CITED
-
- Close
- SHARE
-
- Close
